Bioinformatics Scientists

19-1029.01

Median wage $98,920/yr55,850 employed (US)Rank #134 of 923 scored · top 15% by substitution

Conduct research using bioinformatics theory and methods in areas such as pharmaceuticals, medical technology, biotechnology, computational biology, proteomics, computer information science, biology and medical informatics. May design databases and develop algorithms for processing and analyzing genomic information, or other biological information.

Sub-scores

0–100 · band = confidence interval from rater disagreement

Substitution42

Exposure37

Augmentation74

Substitution — the headline: capability discounted by cost, barriers and adoption.

Exposure — technical capability alone, regardless of whether anyone deploys it.

Augmentation — how much AI assists without replacing. High here + moderate substitution = a changing job, not a disappearing one.

Tasks on the substitution scale

20 rated tasks, binned by substitution score.

Position among all scored occupations

Distribution of 923 occupation scores; the marker is this occupation.

Tasks with substitution ≥ 70

Run 1.0.0-draft.1 · computed 2026-08-05 · rater panel: claude-sonnet-5, claude-haiku-4-5-20251001 · intervals span rater disagreement.

Why this score

The five weighted dimensions of the composite, averaged across this occupation's tasks (importance-weighted, panel mean). Exact weights and formulas: /api/v1/methodology.

Task automatabilityw 35%37

panel mean rating 2.5/5 → substitution pressure 37/100

Technical feasibility todayw 20%38

panel mean rating 2.5/5 → substitution pressure 38/100

Cost vs. human wagew 15%38

panel mean rating 2.5/5 → substitution pressure 38/100

Adoption barriersw 20%inverted — strong barriers lower the score57

panel mean rating 2.7/5 (barrier strength) → substitution pressure 57/100

Sector adoption velocityw 10%49

panel mean rating 3.0/5 → substitution pressure 49/100

Task breakdown (20 tasks)

Substitution pressure per task, weighted by O*NET importance in the composite. Expand a task for the full rater audit trail — every rating, every model, every rationale.

Prepare summary statistics of information regarding human genomes.

CI 75–86 · exposure 80 · augmentation 88 · importance 2.7/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	5/5	Genomics research, biotech, and clinical sequencing labs have rapidly adopted automated summary-statistics pipelines over the past decade; this is now standard practice in large-scale projects (1000 Genomes, UK Biobank, etc.).
Sector adoption velocity	claude-sonnet-5	4/5	Genomics and computational biology are among the more digitized life-science subfields with heavy adoption of automated pipelines and increasing integration of AI/ML tools for analysis.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI-driven statistical summaries and interactive visualization tools substantially augment bioinformaticians' ability to explore and validate patterns in genomic data, accelerating hypothesis generation and quality assurance while humans remain in the loop for interpretation.
Augmentation potential	claude-sonnet-5	5/5	AI and automated statistical/genomics pipelines substantially speed up and standardize summary statistic generation, letting scientists focus on interpretation and hypothesis generation while remaining in the loop for validation.
Task automatability	claude-haiku-4-5-20251001	4/5	Current AI and bioinformatics tools can generate summary statistics (allele frequencies, SNP distributions, etc.) from genomic datasets with minimal human intervention, achieving well over 50% time savings on routine analyses; however, interpretation and validation of unusual findings typically requires human oversight.
Task automatability	claude-sonnet-5	4/5	Computing summary statistics (allele frequencies, coverage, variant counts, QC metrics) from genomic data is highly standardized and scriptable, and current AI/automation pipelines can generate these with minimal human intervention beyond setup and review.
Adoption barriers	claude-haiku-4-5-20251001	2/5	Genomic data is subject to privacy regulations (HIPAA, GDPR) and institutional review, but the statistical summarization task itself—once data is properly handled—has minimal legal requirement for human sign-off; IRB and compliance oversight apply to data access, not the automation of summary statistics.
Adoption barriers	claude-sonnet-5	2/5	No licensing requirement dictates who computes statistics, though data privacy regulations (e.g., HIPAA, GDPR) and scientific validity standards create moderate friction around data handling and reproducibility.
Cost vs. human wage	claude-haiku-4-5-20251001	5/5	Automated pipelines running on commodity compute infrastructure cost orders of magnitude less than manual statistical computation and curation by skilled bioinformaticians.
Cost vs. human wage	claude-sonnet-5	4/5	Automated pipelines running on cloud compute are dramatically cheaper per sample than manual statistical computation by a trained scientist, though initial pipeline development and validation add some cost.
Technical feasibility today	claude-haiku-4-5-20251001	5/5	Mature, production-grade tools (GATK, SAMtools, Plink, bcftools) and cloud-native platforms (AWS Genomics, Google Genomics) reliably perform genomic summary statistics at scale across academic and clinical organizations.
Technical feasibility today	claude-sonnet-5	4/5	Established bioinformatics pipelines (e.g., GATK, PLINK, Bioconductor tools) already automate summary statistic generation in production research and clinical genomics labs, though some customization and validation still requires expert oversight.

Compile data for use in activities, such as gene expression profiling, genome annotation, or structural bioinformatics.

CI 55–79 · exposure 62 · augmentation 75 · importance 3.8/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	4/5	Bioinformatics and genomics sectors are highly digitized, with strong adoption of automated pipelines and workflow management systems in major research labs and biotech companies. Displacement of manual data compilation is well underway.
Sector adoption velocity	claude-sonnet-5	3/5	Life sciences and biotech are adopting computational and AI tools at a moderate pace, with mature pipelines in large genomics centers but slower uptake in smaller academic labs.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI-powered data assembly, anomaly detection, and format conversion substantially raise scientist productivity when integrated into their workflows, allowing them to focus on interpretation and experimental design rather than mechanical compilation.
Augmentation potential	claude-sonnet-5	4/5	AI and automated pipelines substantially speed up data gathering, formatting, and preliminary organization, letting scientists focus on interpretation and hypothesis generation.
Task automatability	claude-haiku-4-5-20251001	4/5	Data compilation for bioinformatics—pulling from databases, formatting sequences, cleaning metadata, and organizing expression matrices—is substantially automatable with current tools. Scripts and AI agents can handle 70–80% of typical workflows, though domain-specific validation and exception handling often require human oversight, preventing a full 5.
Task automatability	claude-sonnet-5	3/5	AI/scripting tools can automate much of the data compilation, formatting, and aggregation from databases, but pipeline setup, quality control, and domain-specific validation still require human oversight for reliable use in downstream analysis.
Adoption barriers	claude-haiku-4-5-20251001	2/5	Few regulatory or legal barriers prevent automation of data compilation itself; it is not a licensed or certified activity. Organizational friction exists (preference to retain in-house curation, data governance policies) but does not prevent substitution.
Adoption barriers	claude-sonnet-5	2/5	No formal licensing requirement for this task, though scientific rigor and reproducibility standards in academic/pharma settings create some friction against unchecked automation.
Cost vs. human wage	claude-haiku-4-5-20251001	5/5	Automated data compilation via cloud compute and open-source pipelines costs orders of magnitude less per task than paying a scientist's loaded wage (typically $100–150k/year) for data wrangling that occupies 20–40% of their time.
Cost vs. human wage	claude-sonnet-5	3/5	Automated data compilation tools reduce labor significantly, but licensing, compute, and the need for expert oversight to validate biological data quality keep costs roughly comparable to a skilled technician's time for complex compilation tasks.
Technical feasibility today	claude-haiku-4-5-20251001	4/5	Mature bioinformatics platforms (Galaxy, QIIME, Nextflow pipelines) and AI-assisted data preparation tools are deployed in production at scale in research institutions and biotech firms. Error rates on routine compilation tasks are low, though complex custom data sources still require manual review.
Technical feasibility today	claude-sonnet-5	3/5	Bioinformatics pipelines (e.g., Nextflow, Galaxy, AI-assisted data retrieval tools) exist in production and are widely used, but they require configuration and domain expertise, and error rates in automated annotation/curation remain non-trivial.

Analyze large molecular datasets, such as raw microarray data, genomic sequence data, or proteomics data, for clinical or basic research purposes.

CI 50–75 · exposure 62 · augmentation 100 · importance 3.9/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	4/5	Genomics and proteomics labs, especially in academic medical centers, biotech, and pharma, have rapidly adopted automated pipelines and AI-driven analysis over the past 5–10 years. Cloud platforms (AWS, Google Cloud) and containerized workflows have accelerated this; adoption is measurable and widespread in the information-intensive biotech sector.
Sector adoption velocity	claude-sonnet-5	3/5	Genomics and computational biology have adopted ML tools substantially, but adoption is uneven across labs and institutions, with many still relying on manual curation and interpretation.
Augmentation potential	claude-haiku-4-5-20251001	5/5	AI augments bioinformatics scientists substantially: automated preprocessing, predictive models, visualization tools, and hypothesis-generation algorithms all enhance productivity while scientists retain control over interpretation, experimental design, and clinical translation. This is one of the strongest augmentation-only scenarios in data science.
Augmentation potential	claude-sonnet-5	5/5	AI dramatically accelerates data preprocessing, pattern recognition, and hypothesis generation in genomic/proteomic analysis, significantly boosting scientist productivity while humans retain interpretive and decision-making roles.
Task automatability	claude-haiku-4-5-20251001	4/5	Large portions of this task can be automated: preprocessing raw data, quality control, alignment, normalization, and basic statistical analysis are handled by mature pipelines and AI tools (e.g., standard bioinformatics packages, ML models for variant calling). However, interpretation of results and hypothesis formulation typically require human judgment, so full end-to-end autonomy with 50% time saving is achievable for the technical steps but not the complete analytical task.
Task automatability	claude-sonnet-5	3/5	AI/ML pipelines can automate substantial portions of data processing, normalization, and pattern detection, but experimental design, quality control judgment calls, and biological interpretation still require significant human expertise, limiting full end-to-end automation.
Adoption barriers	claude-haiku-4-5-20251001	2/5	Few legal or licensing barriers exist for computational analysis itself; however, data privacy (HIPAA, GDPR) and institutional review board (IRB) oversight introduce moderate friction for clinical datasets. Most automation does not require human sign-off by law, though best practices and publication standards often demand expert validation of results.
Adoption barriers	claude-sonnet-5	3/5	Clinical research applications often require validated, auditable pipelines and human sign-off for regulatory and scientific integrity reasons, though basic research settings have fewer formal constraints.
Cost vs. human wage	claude-haiku-4-5-20251001	4/5	Automated data processing pipelines and cloud-based bioinformatics services have very low marginal cost per dataset once set up (often <$100–500 per analysis), whereas hiring a bioinformatics scientist runs $80–150k+ annually. The cost advantage is substantial, though upfront infrastructure and licensing costs must be amortized.
Cost vs. human wage	claude-sonnet-5	3/5	Compute costs for large-scale analysis are substantial and specialized infrastructure/expertise is still needed to interpret results, making the cost advantage over skilled human scientists moderate rather than dramatic.
Technical feasibility today	claude-haiku-4-5-20251001	4/5	Deployed products and established workflows (GATK, samtools, DESeq2, proteomics software suites) perform large parts of this task reliably in production across genomics and proteomics labs. AI-assisted interpretation tools and machine learning models for phenotype prediction also operate at scale, though some edge cases and novel data types still require expert oversight.
Technical feasibility today	claude-sonnet-5	3/5	Production bioinformatics tools (e.g., automated variant callers, expression analysis pipelines) are widely deployed, but they still require expert configuration and validation, and are not fully autonomous for novel or complex datasets.

Develop new software applications or customize existing applications to meet specific scientific project needs.

CI 38–75 · exposure 50 · augmentation 88 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	4/5	Bioinformatics and computational biology are information-intensive, digitally native fields with high adoption of AI coding tools. Professional services and tech-adjacent sectors show rapid production deployment of AI-assisted development; bioinformatics teams at major research institutions and biotech firms are already integrating these tools.
Sector adoption velocity	claude-sonnet-5	3/5	Research and biotech/pharma sectors are moderately fast adopters of AI coding tools, with pilots and partial integration common, though full autonomous application development is still rare.
Augmentation potential	claude-haiku-4-5-20251001	5/5	AI coding assistants substantially amplify bioinformatics scientist productivity by handling syntax, boilerplate, testing scaffolds, and documentation—allowing experts to focus on algorithm design, validation, and scientific interpretation. The human remains in full control while output quality and speed improve dramatically.
Augmentation potential	claude-sonnet-5	4/5	AI substantially speeds up coding, debugging, and documentation for bioinformatics developers, serving as a strong productivity multiplier while humans retain design and validation control.
Task automatability	claude-haiku-4-5-20251001	4/5	Code generation AI (GPT-4, Copilot, Claude) can already handle a substantial portion of bioinformatics software development—boilerplate, scaffolding, testing, and routine feature implementation—delivering >50% time savings in many workflows. However, novel algorithm design and complex architectural decisions still require human oversight.
Task automatability	claude-sonnet-5	2/5	AI coding assistants can accelerate scripting and boilerplate generation, but scientific software development requires domain-specific algorithm design, validation against biological data, and iterative debugging that current AI cannot fully own end-to-end.
Adoption barriers	claude-haiku-4-5-20251001	2/5	Few regulatory or licensing barriers exist to using AI for internal tool development in academic or commercial bioinformatics. Organizations may require code review and validation, but no law forbids AI-assisted coding, and adoption is driven mainly by developer preference and organizational practice rather than legal gates.
Adoption barriers	claude-sonnet-5	2/5	No licensing requirement restricts who writes bioinformatics software, but correctness for scientific validity and reproducibility creates strong organizational and quality-control friction against full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	4/5	AI inference costs for code generation are typically dollars per task, while bioinformatics scientists earn $80–130k annually (~$40–65/hour). AI-assisted development yields cost-per-output of 5–10× cheaper than solo human development, though not yet order-of-magnitude cheaper for the full pipeline including testing.
Cost vs. human wage	claude-sonnet-5	2/5	AI coding tools reduce some development time cheaply, but the human oversight, debugging, and domain validation needed still dominate costs, keeping overall savings modest rather than order-of-magnitude.
Technical feasibility today	claude-haiku-4-5-20251001	4/5	Deployed products (GitHub Copilot, ChatGPT, specialized coding assistants) demonstrably perform code generation and customization in production for bioinformatics teams, with measurable productivity gains. Minor limitations remain in very specialized domain logic and multi-package integration complexities.
Technical feasibility today	claude-sonnet-5	2/5	Deployed code-generation tools (e.g., Copilot, Codex-based assistants) are used by bioinformaticians for snippets and utility scripts, but no product reliably builds or customizes full scientific applications autonomously in production.

Manipulate publicly accessible, commercial, or proprietary genomic, proteomic, or post-genomic databases.

CI 32–79 · exposure 50 · augmentation 75 · importance 3.7/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	4/5	Bioinformatics and computational biology sectors are highly digitized and early adopters of automation; API-driven workflows and automated pipelines are now standard in research labs and pharma companies, though some legacy operations remain partially manual.
Sector adoption velocity	claude-sonnet-5	3/5	Life sciences and bioinformatics are increasingly adopting AI coding tools and pipeline automation, though full production-scale agentic adoption for database manipulation remains uneven and pilot-heavy.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI and automation substantially boost scientist productivity by handling routine querying, formatting, and data retrieval, freeing them for analysis and interpretation. Tools like LLMs can also help construct complex queries and troubleshoot database access issues.
Augmentation potential	claude-sonnet-5	4/5	AI coding assistants (e.g., Copilot-style tools) substantially speed up writing queries, scripts, and data wrangling code for genomic databases, meaningfully boosting scientist productivity while they remain in control.
Task automatability	claude-haiku-4-5-20251001	4/5	Most of the task—querying, filtering, exporting, and reformatting genomic data from standard databases—can be automated with current AI and scripting tools. However, complex data integration across proprietary formats and validation of results for scientific accuracy typically require human oversight, preventing a full 5.
Task automatability	claude-sonnet-5	2/5	Database manipulation (querying, merging, filtering large genomic/proteomic datasets) can be partially scripted and AI-assisted, but requires domain-specific pipeline design, format handling, and validation that current systems cannot fully replace end-to-end.
Adoption barriers	claude-haiku-4-5-20251001	3/5	Moderate friction exists: proprietary databases require authentication and licensing, some require institutional agreements, and data governance policies may restrict automation. However, no legal requirement mandates human execution of the task itself.
Adoption barriers	claude-sonnet-5	2/5	No licensing requirement, but proprietary database access agreements, data governance policies, and the need for domain expertise to avoid costly errors create moderate friction.
Cost vs. human wage	claude-haiku-4-5-20251001	5/5	Automated queries via APIs or command-line tools are orders of magnitude cheaper than paying a scientist's time (loaded wage $80k–$150k/year) to manually download and reformat the same data repeatedly.
Cost vs. human wage	claude-sonnet-5	2/5	While AI can reduce time on scripting portions, the need for expert oversight of data integrity, format quirks, and scientific validity keeps overall costs closer to human-comparable rather than order-of-magnitude cheaper.
Technical feasibility today	claude-haiku-4-5-20251001	4/5	Multiple production systems exist (NCBI APIs, Galaxy, Ensembl pipelines, commercial bioinformatics platforms) that reliably perform database queries, downloads, and basic manipulation at scale. Some edge cases and novel data formats may require manual intervention, keeping this slightly below 5.
Technical feasibility today	claude-sonnet-5	2/5	AI coding assistants can help write scripts to query and manipulate bioinformatics databases, but no deployed product reliably performs full database manipulation workflows autonomously at production scale in research settings.

Create novel computational approaches and analytical tools as required by research goals.

CI 38–70 · exposure 45 · augmentation 88 · importance 4.2/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	4/5	Bioinformatics is information-dense, digitally native, and highly represented in technology-forward sectors (biotech, pharma, academia). AI coding tools have already achieved rapid adoption among computational scientists and are actively transforming research workflows.
Sector adoption velocity	claude-sonnet-5	3/5	Life sciences and bioinformatics are increasingly adopting AI/ML tools and coding copilots, though deep production-level automation of novel research method creation remains uncommon.
Augmentation potential	claude-haiku-4-5-20251001	5/5	AI significantly amplifies bioinformatics scientist productivity by accelerating code generation, suggesting algorithmic approaches, and enabling rapid prototyping of novel tools—while the scientist retains design authority, validation, and biological interpretation.
Augmentation potential	claude-sonnet-5	4/5	AI coding assistants, literature synthesis tools, and ML libraries significantly speed up prototyping, debugging, and exploring algorithmic variants, substantially boosting researcher productivity while humans retain creative control.
Task automatability	claude-haiku-4-5-20251001	4/5	AI can now generate, modify, and optimize code for novel computational tools, and can propose algorithmic approaches based on literature and domain patterns. However, the creative research goal-setting and validation of novel approaches against experimental biology still requires human judgment, preventing a full 5.
Task automatability	claude-sonnet-5	2/5	Designing genuinely novel computational approaches requires original scientific judgment, hypothesis generation, and creative problem-solving that current AI cannot reliably perform end-to-end without heavy human direction.dev ArationaleAI can help code and prototype but not conceive novel methods autonomously.
Adoption barriers	claude-haiku-4-5-20251001	2/5	No legal requirement mandates a human create these tools; academic and industry research labs have minimal regulatory barriers to adopting AI-assisted development. The main friction is institutional preference for scientist validation and peer review, not hard legal barriers.
Adoption barriers	claude-sonnet-5	2/5	No licensing requirement blocks AI use, though publication norms, peer review, and scientific credibility standards create some friction against fully automated novel method development.
Cost vs. human wage	claude-haiku-4-5-20251001	4/5	AI inference and integration costs are very low compared to the loaded salary of a bioinformatics scientist ($100k+/year). One researcher using AI tools can accomplish work previously requiring multiple people, making the cost ratio heavily favoring automation.
Cost vs. human wage	claude-sonnet-5	2/5	Skilled bioinformatics scientists command high wages, but developing novel tools still requires extensive human expert time for validation and iteration, limiting cost savings from AI assistance alone.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Products like GitHub Copilot, Claude, and GPT-4 can assist with code generation and suggest novel methods in production settings, but their outputs still require substantial expert review, debugging, and domain validation before deployment in research pipelines.
Technical feasibility today	claude-sonnet-5	2/5	Coding assistants and LLMs can help implement algorithms or suggest approaches, but no deployed product reliably originates novel bioinformatics methodologies in production settings.

Develop data models and databases.

CI 35–70 · exposure 45 · augmentation 88 · importance 3.8/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	4/5	Bioinformatics and life-sciences informatics sectors show rapid adoption of AI coding tools (Copilot, ChatGPT) for database and data-model development, with many research institutions and biotech firms now deploying these tools in production pipelines.
Sector adoption velocity	claude-sonnet-5	2/5	placeholder
Augmentation potential	claude-haiku-4-5-20251001	5/5	AI significantly augments bioinformatics scientists by rapidly drafting schemas, generating boilerplate, and suggesting optimizations, allowing humans to focus on domain validation, edge-case handling, and ensuring biological accuracy while remaining fully in control of model design decisions.
Augmentation potential	claude-sonnet-5	4/5	placeholder
Task automatability	claude-haiku-4-5-20251001	4/5	AI can generate database schemas, optimize data structures, and even draft complete data models from specifications using code generation and LLM tools, achieving substantial time savings (>50%) on routine modeling tasks; human judgment remains needed for validation but most of the computational work is automatable.
Task automatability	claude-sonnet-5	2/5	Data modeling and database design require domain-specific judgment about biological data relationships, schema tradeoffs, and downstream analytical needs that current AI can assist with but not fully replace end-to-end at high quality.<br>Significant human architecture decisions remain necessary.》Wait, keeping simple.}}
Adoption barriers	claude-haiku-4-5-20251001	2/5	Limited regulatory or licensing barriers exist for data modeling itself; adoption is primarily constrained by organizational preference for domain expert validation and internal review processes rather than legal or compliance mandates.
Adoption barriers	claude-sonnet-5	2/5	placeholder
Cost vs. human wage	claude-haiku-4-5-20251001	4/5	AI-assisted code generation and schema synthesis costs (API inference + integration) are substantially lower than the fully loaded labor cost of a senior bioinformatics scientist for routine model development, though complex custom implementations may narrow the gap.
Cost vs. human wage	claude-sonnet-5	2/5	placeholder
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Deployed products (GitHub Copilot, Claude, specialized ML frameworks) can reliably generate code and schema templates for data modeling, but production systems still require significant human oversight to ensure biological domain correctness, data integrity constraints, and alignment with downstream analysis requirements.
Technical feasibility today	claude-sonnet-5	2/5	placeholder

Create or modify web-based bioinformatics tools.

CI 30–55 · exposure 42 · augmentation 75 · importance 3.4/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	While software development is digitized, the bioinformatics sector moves cautiously on automation of tool creation due to validation requirements, distributed institutional research practices, and low absolute volumes of such roles. Adoption of AI-driven tool generation is in early pilot phases rather than production deployment.
Sector adoption velocity	claude-sonnet-5	3/5	Software development broadly has fast AI tool adoption, but specialized scientific/bioinformatics software development lags general web development in AI-driven workflow integration.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI code assistants materially enhance bioinformatics scientist productivity by generating boilerplate, suggesting algorithms, and accelerating debugging, allowing scientists to focus on research logic and validation. This is already in active use and transforms the efficiency of tool development while keeping domain experts in control.
Augmentation potential	claude-sonnet-5	4/5	AI coding assistants substantially speed up scaffolding, debugging, and modifying web-based tools, letting bioinformatics scientists focus more on domain logic and validation.
Task automatability	claude-haiku-4-5-20251001	2/5	Creating or modifying web-based bioinformatics tools requires significant domain-specific knowledge, architectural decisions, and integration of complex biological algorithms. While AI can assist with code generation and debugging, the end-to-end design, validation, and testing of scientifically correct tools falls short of the 50% time-saving threshold for full automation.
Task automatability	claude-sonnet-5	3/5	AI coding assistants can generate significant portions of web application code and bioinformatics scripts, but integrating domain-specific pipelines, databases, and biological data validation still requires substantial human design and testing.4
Adoption barriers	claude-haiku-4-5-20251001	4/5	Scientific tools require validation, documentation, and often institutional review or regulatory approval for clinical/research use. Reproducibility, correctness verification, and organizational governance over research tools create meaningful friction that prevents simple substitution of human expertise with automated development.
Adoption barriers	claude-sonnet-5	2/5	No licensing requirement for building software tools, though correctness and validation for scientific use creates moderate organizational scrutiny and quality control friction.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	AI-assisted code generation reduces some development costs, but the loaded cost of a bioinformatics scientist (domain expertise, validation, debugging scientific correctness) remains substantial. AI tools still require significant human oversight and iteration, making the all-in cost only moderately lower than traditional development.
Cost vs. human wage	claude-sonnet-5	3/5	AI-assisted coding reduces developer time substantially, but the specialized nature of bioinformatics tools (data formats, algorithms, validation) still requires expensive expert review, keeping costs roughly comparable to human-only development at scale.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Code generation tools (GitHub Copilot, Claude) and low-code platforms can handle routine web development components, but deployed products lack reliable integration of novel bioinformatics algorithms, proper scientific validation, and deployment in production research environments at scale.
Technical feasibility today	claude-sonnet-5	3/5	Deployed AI coding tools (Copilot, Claude, etc.) reliably assist in building web applications and scripting, but no production system autonomously builds and maintains full bioinformatics web tools without expert oversight.

Provide statistical and computational tools for biologically based activities, such as genetic analysis, measurement of gene expression, or gene function determination.

CI 32–49 · exposure 38 · augmentation 75 · importance 3.4/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	4/5	Bioinformatics and computational biology are highly digitized sectors with rapid adoption of ML-based tools, cloud pipelines, and automated workflows; major research institutions, biotech firms, and pharma companies are actively deploying AI-assisted analysis at scale. Adoption is faster than traditional lab-based work but slower than pure software engineering.
Sector adoption velocity	claude-sonnet-5	3/5	Life sciences and bioinformatics have seen growing adoption of AI/ML tools (e.g., in genomics pipelines), but full autonomous tool development and deployment remains at pilot/tool-assisted stage rather than deep production automation.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI tools substantially augment bioinformaticians' productivity by automating routine statistical calculations, generating hypotheses from large datasets, and accelerating exploratory analysis while scientists remain responsible for interpretation and validation. Modern tools like deep-learning gene predictors and automated statistical reporting directly amplify expert productivity.
Augmentation potential	claude-sonnet-5	4/5	AI significantly augments this task by assisting with code generation, statistical method selection, literature synthesis, and pipeline debugging, meaningfully increasing scientist productivity while humans retain interpretive control.
Task automatability	claude-haiku-4-5-20251001	3/5	Current AI systems can automate significant portions of statistical analysis, gene expression quantification, and data processing pipelines, but require substantial human expertise in study design, hypothesis formulation, and interpretation of biological significance. The variability in experimental contexts and the need for domain judgment on what constitutes valid methodology prevent full end-to-end automation at the 50% threshold.
Task automatability	claude-sonnet-5	2/5	AI can help write analysis scripts and select statistical methods, but designing, validating, and maintaining robust bioinformatics pipelines for genetic/expression analysis requires deep domain expertise and iterative human judgment that current AI cannot fully replace end-to-end.
Adoption barriers	claude-haiku-4-5-20251001	3/5	Publication and peer review expectations create friction around reproducibility and methodological transparency; regulatory requirements for clinical applications (e.g., FDA guidelines on computational validation) add modest barriers. However, no hard legal requirement mandates human sign-off on the computational methods themselves, only on the biological conclusions and clinical decisions.
Adoption barriers	claude-sonnet-5	3/5	No licensing requirement per se, but scientific rigor, reproducibility standards, peer review, and the high cost of erroneous biological conclusions create moderate friction against full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	While computational inference is cheap, the integration of tools into coherent pipelines, validation, and the specialized human oversight required to ensure biological correctness remain significant costs. The all-in cost of AI-assisted analysis often approaches or exceeds hiring a bioinformatician, particularly for non-routine applications.
Cost vs. human wage	claude-sonnet-5	2/5	While AI can reduce time on code generation and literature review, the human expert oversight, validation, and domain-specific tool development still dominate costs, keeping AI only modestly cheaper for the full task.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Deployed bioinformatics tools and ML-based gene expression analysis platforms (e.g., differential expression callers, variant calling pipelines) perform reliably on standard tasks, but material limitations remain in handling novel experimental designs, edge cases, and requiring expert parameter tuning. Production systems exist but often require specialist oversight rather than fully autonomous operation.
Technical feasibility today	claude-sonnet-5	2/5	Coding assistants and specialized tools (e.g., AlphaFold, some AI-based variant callers) exist, but no deployed product autonomously provides comprehensive statistical/computational toolsets for gene expression or function analysis reliably at scale in production research settings.

Collaborate with software developers in the development and modification of commercial bioinformatics software.

CI 32–45 · exposure 30 · augmentation 75 · importance 2.8/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	4/5	Software development and life sciences sectors show relatively rapid adoption of AI coding assistants; major research institutions and biotech firms actively integrate Copilot and similar tools into development workflows, with measurable productivity gains in production pipelines.
Sector adoption velocity	claude-sonnet-5	3/5	Software development broadly has seen fast AI tool adoption (copilots, code generation), and bioinformatics/biotech is increasingly digitized, though this specific cross-functional collaborative task adopts more slowly than pure coding tasks.
Augmentation potential	claude-haiku-4-5-20251001	4/5	Code generation and documentation AI markedly accelerates code drafting, testing, and debugging for bioinformatics developers, reducing boilerplate work and freeing scientists to focus on algorithm design and biological interpretation. Human scientists remain essential for validation and strategic decisions.
Augmentation potential	claude-sonnet-5	4/5	AI coding assistants, documentation tools, and code review aids can meaningfully speed up the software development portions of this collaboration while humans retain oversight and domain judgment.
Task automatability	claude-haiku-4-5-20251001	2/5	While AI can assist with code generation and review, bioinformatics software development requires deep domain knowledge, architectural decisions, and coordination with human developers. AI cannot autonomously manage the full development lifecycle, requirements gathering, or cross-functional collaboration at >50% time savings with equal quality.
Task automatability	claude-sonnet-5	2/5	This is an inherently collaborative, judgment-heavy task involving requirements gathering, domain expertise translation, and iterative design decisions that resist full automation, though AI can assist parts like code drafting or documentation.
Adoption barriers	claude-haiku-4-5-20251001	3/5	Bioinformatics software development for clinical or regulated applications may require human accountability and code review by qualified professionals. Organizational preference for human domain expertise and collaborative oversight creates moderate friction, though no strict licensing requirement prevents AI-augmented development.
Adoption barriers	claude-sonnet-5	2/5	No licensing requirement blocks AI involvement, but organizational processes, code review standards, and the need for domain trust in commercial software create moderate friction.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	AI coding assistants are cheap per inference (~$0.01–0.10 per task), but integration, validation, and human oversight add significant cost. A senior bioinformatics scientist's loaded wage (~$150–200k/year) amortizes to ~$75/hour, making the all-in cost of AI-assisted development still substantially less than pure human labor, though not by an order of magnitude.
Cost vs. human wage	claude-sonnet-5	2/5	AI tools can reduce some coding and documentation time, but the collaborative human-to-human coordination and domain-specific validation still require substantial human involvement, keeping costs comparable to human-driven work.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Code generation tools (Copilot, ChatGPT) are deployed in many development environments and can produce working code snippets, but they lack the context-aware decision-making needed for complex bioinformatics projects. Material error rates remain in algorithm correctness and domain-specific optimization.
Technical feasibility today	claude-sonnet-5	2/5	AI coding assistants exist and are used in software development workflows, but no product autonomously handles the collaborative, cross-disciplinary bioinformatics-specific software development process end-to-end.

Keep abreast of new biochemistries, instrumentation, or software by reading scientific literature and attending professional conferences.

CI 13–64 · exposure 30 · augmentation 63 · importance 3.9/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	While information-sector adoption is generally fast, the specific practice of keeping abreast through reading and conferences remains slow to automate because it is tied to individual professional identity and institutional expectations. Adoption of assistive tools (summarization) is modest; replacement is minimal.
Sector adoption velocity	claude-sonnet-5	3/5	Life sciences and bioinformatics are moderately fast adopters of AI research tools (e.g., literature summarizers, semantic search), but full integration into daily workflows is still uneven across labs.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI literature summarization and recommendation tools can usefully help a scientist filter and synthesize papers, raising the efficiency of the reading process. However, the human must still engage critically with the content, so augmentation is meaningful but not transformative.
Augmentation potential	claude-sonnet-5	4/5	AI substantially augments this task by enabling rapid literature triage, summarization, and trend spotting, letting scientists focus attention on higher-value dissemination like conferences and deep reading.
Task automatability	claude-haiku-4-5-20251001	1/5	This task requires human judgment to assess relevance, synthesize new findings, and maintain domain expertise. While AI can help retrieve and summarize papers, the core activity—staying intellectually current and deciding what matters for one's research—remains fundamentally human and cannot be automated end-to-end.
Task automatability	claude-sonnet-5	3/5	AI can summarize literature, flag relevant papers, and synthesize conference abstracts, saving significant time, but cannot fully replace attending conferences or the judgment needed to assess novel biochemistries/instrumentation.ed
Adoption barriers	claude-haiku-4-5-20251001	4/5	Strong organizational and professional norms require individual scientists to maintain their own expertise and stay current; funding agencies and institutions expect researchers to be conversant with their field. Conference attendance is often a personal professional investment tied to credentialing and networking.
Adoption barriers	claude-sonnet-5	1/5	There is no licensing or regulatory requirement mandating a human perform literature review or attend conferences; it's a professional development task with minimal formal barriers.
Cost vs. human wage	claude-haiku-4-5-20251001	1/5	The cost of deploying AI to systematically monitor and summarize literature at the scale a bioinformatics scientist requires (plus oversight) would exceed the cost of the scientist's own time spent reading, especially given the low scalability of knowledge updates across a diverse research landscape.
Cost vs. human wage	claude-sonnet-5	4/5	AI-based literature monitoring and summarization tools are inexpensive relative to a scientist's time spent manually scanning journals, though some human review is still needed to validate accuracy.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	AI can assist with literature retrieval and summarization (e.g., PubMed search tools, research assistants), but no deployed product reliably substitutes for a scientist's own reading and conference attendance. The task is inherently about human learning and professional engagement.
Technical feasibility today	claude-sonnet-5	3/5	Deployed tools like literature summarization assistants, alerting services, and RAG-based research copilots exist and are used by scientists, but coverage of cutting-edge conference content and nuanced technical evaluation remains limited.

Design and apply bioinformatics algorithms including unsupervised and supervised machine learning, dynamic programming, or graphic algorithms.

CI 32–42 · exposure 30 · augmentation 75 · importance 3.7/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	3/5	Bioinformatics has moderate adoption of AI tools for specific subtasks (alignment, variant calling), but full end-to-end algorithm design remains largely researcher-driven. Academic and biotech sectors show pilot adoption of ML-assisted design, but production replacement of the design phase is still uncommon.
Sector adoption velocity	claude-sonnet-5	3/5	Life sciences and computational biology are adopting AI coding tools and ML frameworks at a moderate pace, with pilots and partial integration common but full autonomous algorithm design still rare.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI significantly assists bioinformatics scientists by automating code generation, parameter tuning, literature search, and validation testing, substantially raising productivity in algorithm implementation and refinement while the scientist retains design and interpretation authority.
Augmentation potential	claude-sonnet-5	4/5	AI coding assistants and ML libraries significantly speed up implementation, debugging, and exploration of algorithmic approaches, meaningfully boosting productivity while the scientist retains design authority.
Task automatability	claude-haiku-4-5-20251001	2/5	While AI can assist in implementing existing algorithms and optimizing code, designing novel bioinformatics algorithms requires domain expertise, creative problem-solving, and validation against biological constraints that current systems cannot fully automate. The design phase—selecting appropriate algorithmic approaches, setting parameters, and validating biological relevance—remains heavily dependent on human judgment and experimentation.
Task automatability	claude-sonnet-5	2/5	Designing novel bioinformatics algorithms requires deep domain expertise, mathematical reasoning, and validation against biological data that current AI cannot autonomously perform end-to-end; AI can assist with code generation but not the core scientific design process.rate.
Adoption barriers	claude-haiku-4-5-20251001	3/5	Regulatory and publication standards require validation and reproducibility of bioinformatics methods, and institutional practices favor human scientists as accountable designers. However, no strict licensing requirement prevents AI assistance, and organizations are beginning to adopt AI tools for parts of this workflow.
Adoption barriers	claude-sonnet-5	2/5	No licensing requirement exists for algorithm design itself, though downstream clinical or research applications may face regulatory scrutiny; the main barrier is technical competence rather than formal authorization.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	AI tools reduce some implementation and optimization costs, but the expertise required for algorithm design and validation means a bioinformatics scientist's labor remains substantial and often irreplaceable. The all-in cost (infrastructure, compute, human review) does not yet undercut the cost of experienced domain expertise.
Cost vs. human wage	claude-sonnet-5	2/5	Human bioinformatics scientists command high wages, but the AI still requires substantial expert oversight and iteration for algorithm design, so total cost savings are modest rather than order-of-magnitude.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Deployed tools (AutoML platforms, code-generation LLMs, algorithm libraries) can implement standard algorithms and optimize existing ones in production settings, but designing and applying novel algorithms to new biological problems still requires significant human oversight and domain validation. Products exist for parts of this workflow but lack end-to-end autonomous design capability.
Technical feasibility today	claude-sonnet-5	2/5	AI coding assistants can help implement known algorithms (e.g., writing dynamic programming code) but no deployed product autonomously designs novel bioinformatics algorithms in production settings.

Instruct others in the selection and use of bioinformatics tools.

CI 30–41 · exposure 25 · augmentation 75 · importance 2.9/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Bioinformatics training remains largely delivered by expert researchers and technicians in academic and research settings where human instruction is valued. Adoption of AI tutoring systems is slow relative to sectors like customer support or general education.
Sector adoption velocity	claude-sonnet-5	3/5	Bioinformatics and life sciences are increasingly using AI copilots and documentation tools, but adoption for structured training/instruction specifically remains in early pilot stages.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI can meaningfully assist by generating tutorial drafts, creating supplementary examples, or producing documentation that an instructor then refines and delivers—substantially raising their productivity without removing the instructional role.
Augmentation potential	claude-sonnet-5	4/5	AI can significantly augment instruction by generating tutorials, answering technical questions, and providing on-demand explanations of tool functionality, complementing human instructors well.
Task automatability	claude-haiku-4-5-20251001	2/5	While AI can generate written documentation or create tutorial content, instructing others requires adaptive communication, reading comprehension of learner needs, and real-time troubleshooting—tasks that remain difficult for current systems. The task has a significant interactive component that resists full automation.
Task automatability	claude-sonnet-5	2/5	Teaching others to use bioinformatics tools requires interactive judgment, tailoring to learner background, and hands-on troubleshooting that current AI cannot fully replicate end-to-end, though it can support parts like documentation or Q&A.
Adoption barriers	claude-haiku-4-5-20251001	3/5	Organizations value direct human expertise and mentorship in technical training, particularly for specialized tools. There is modest organizational friction and quality preference for human instruction, though no hard legal requirement.
Adoption barriers	claude-sonnet-5	2/5	No licensing requirement exists for teaching tool use, but organizational preference for expert-led training and the need for domain-specific judgment create moderate friction against full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	Creating high-quality instructional content requires substantial human oversight and domain expertise. The all-in cost of AI-generated instruction (prompt engineering, validation, remediation) remains high relative to recording a bioinformatician's time.
Cost vs. human wage	claude-sonnet-5	3/5	AI-assisted tutorials or chat support are cheap per query, but effective instruction still requires human expert time for curriculum design, live demonstration, and context-specific guidance, keeping overall cost comparable to human-led training.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	Deployed educational AI (chatbots, video generators) exists but struggles with domain-specific tool instruction and adapting to diverse learner backgrounds. No production system reliably substitutes for expert instruction in specialized bioinformatics contexts at consistent quality.
Technical feasibility today	claude-sonnet-5	2/5	AI chatbots and documentation assistants exist that can answer tool-usage questions, but no deployed product reliably substitutes for structured instruction or mentorship in bioinformatics tool selection at scale.

Test new and updated bioinformatics tools and software.

CI 30–38 · exposure 25 · augmentation 63 · importance 2.8/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Bioinformatics is a specialized, research-heavy field where adoption of generic AI testing has been slow; most labs still rely on manual expert testing and established validation protocols rather than AI-driven automation at scale.
Sector adoption velocity	claude-sonnet-5	3/5	Software engineering and QA broadly show fast AI tool adoption (code assistants, automated testing), but bioinformatics-specific testing workflows are a narrower niche with slower specialized uptake.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI can assist by generating test cases, running automated benchmarks, and flagging anomalies, helping human testers focus on interpreting results and validating scientific soundness, though the human remains essential to the process.
Augmentation potential	claude-sonnet-5	4/5	AI coding assistants meaningfully speed up writing test scripts, identifying edge cases, and generating documentation, substantially aiding the human tester even though full automation is not achieved.
Task automatability	claude-haiku-4-5-20251001	2/5	Testing software requires domain expertise to validate correctness, design meaningful test cases, and interpret results. While AI can assist with test generation and basic execution, the judgement about whether a bioinformatics tool produces scientifically valid results demands human expertise and falls short of the 50% time-saving threshold for end-to-end automation.
Task automatability	claude-sonnet-5	2/5	AI can help draft test cases or scripts, but validating scientific software correctness, edge cases, and biological data behavior requires substantial human judgment and domain expertise that current AI cannot fully replace end-to-end.
Adoption barriers	claude-haiku-4-5-20251001	3/5	There are moderate barriers: regulatory/publication standards often require documented human validation of bioinformatics methods, and institutional quality assurance processes typically mandate expert sign-off on tool correctness before deployment, creating some friction to full automation.
Adoption barriers	claude-sonnet-5	2/5	No licensing requirement, but organizational trust and scientific rigor norms mean testing of research-critical tools typically requires expert sign-off, creating moderate friction.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	Setting up and validating AI-driven testing frameworks, combined with the required human review of bioinformatics results, makes the total cost comparable to or potentially higher than direct human testing, especially given the cost of errors in scientific validation.
Cost vs. human wage	claude-sonnet-5	2/5	AI can cheaply generate unit tests or check syntax, but thorough validation against biological ground truth still requires expert oversight, so overall cost savings versus a skilled bioinformatician are limited.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	General-purpose test automation tools exist, but bioinformatics testing involves validating algorithmic correctness against biological datasets and benchmarks—a specialized domain where deployed AI products demonstrably lack the capability to perform reliably without human oversight.
Technical feasibility today	claude-sonnet-5	2/5	Coding assistants and AI test-generation tools exist and are used for general software QA, but no deployed product reliably validates specialized bioinformatics tools against domain-specific correctness criteria in production.

Communicate research results through conference presentations, scientific publications, or project reports.

CI 28–37 · exposure 30 · augmentation 75 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	3/5	Academic institutions are piloting AI writing tools and showing interest in productivity gains, but adoption remains inconsistent. Most bioinformatics scientists still do significant manual writing; adoption has not reached deep production replacement as seen in finance or IT.
Sector adoption velocity	claude-sonnet-5	3/5	Academic and biotech research settings show moderate, growing use of AI writing tools, but adoption for actual dissemination (presentations, publications) remains cautious due to norms and disclosure requirements.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI writing assistants meaningfully boost productivity by handling initial drafts, editing suggestions, and slide generation, allowing scientists to focus on analysis and narrative structure. Many researchers report productivity gains while retaining full control over message and accountability.
Augmentation potential	claude-sonnet-5	4/5	AI substantially speeds up drafting of abstracts, slides, figures captions, and manuscript sections, letting scientists focus more time on analysis and communication strategy while remaining the responsible author/presenter.
Task automatability	claude-haiku-4-5-20251001	2/5	Current AI can draft sections of scientific publications and generate presentation slides from data, but cannot independently select key findings, interpret results in disciplinary context, or craft a narrative that meets peer-review standards. Significant human judgment and domain expertise remain essential for communicating research integrity.
Task automatability	claude-sonnet-5	2/5	AI can draft slide outlines, summarize results, and produce first-pass manuscript text, but synthesizing novel research findings into a coherent, defensible narrative and presenting it credibly to peers requires human judgment and accountability that current AI cannot fully replace end-to-end.'
Adoption barriers	claude-haiku-4-5-20251001	4/5	Academic and professional reputation, peer-review gatekeeping, and institutional accountability for research integrity create strong barriers. Scientists must personally vouch for results; conference organizers and journals require human authorship accountability and sign-off, preventing pure delegation.
Adoption barriers	claude-sonnet-5	3/5	No licensing requirement bars AI use, but journal authorship norms, scientific integrity standards, and peer expectations of human authorship and presence at conferences create meaningful institutional friction.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	AI writing and slide tools reduce drafting time but require extensive expert review and rewriting, leaving total cost only modestly below hiring a human communicator or having the scientist do it directly. Integration and oversight overhead limits cost advantage.
Cost vs. human wage	claude-sonnet-5	2/5	AI drafting tools are cheap per use, but the need for extensive scientist review, fact-checking, and presentation delivery keeps total cost close to human-driven effort rather than an order-of-magnitude reduction.
Technical feasibility today	claude-haiku-4-5-20251001	3/5	Tools like GPT-based writing assistants and slide generators exist and are deployed in academic settings, but they produce material with substantive errors, miss nuanced interpretations, and require heavy human revision. No product reliably generates publication-ready or presentation-quality output without expert oversight.
Technical feasibility today	claude-sonnet-5	2/5	Writing-assistant and slide-generation tools are deployed and used by researchers, but no product reliably produces publication-ready scientific communication or delivers conference presentations without heavy human revision and oversight.

Improve user interfaces to bioinformatics software and databases.

CI 25–38 · exposure 25 · augmentation 63 · importance 3.4/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Bioinformatics institutions adopt AI tools primarily for data analysis and research acceleration rather than UI/UX automation. UI improvement remains a lower priority, discretionary task often handled by small teams with limited digital-first culture compared to consumer software sectors.
Sector adoption velocity	claude-sonnet-5	3/5	Software development and life sciences tech sectors show moderate AI coding tool adoption, with AI-assisted development becoming common but specialized scientific UI work lags behind general software adoption.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI can assist by generating design mockups, suggesting layouts, and automating routine code changes, which helps bioinformatics scientists iterate faster. However, the core task of understanding user needs and making domain-informed design choices still requires human expertise and user feedback loops.
Augmentation potential	claude-sonnet-5	4/5	AI coding assistants (e.g., GitHub Copilot, generative UI tools) meaningfully speed up prototyping, code generation, and iteration for interface development while developers retain design and domain oversight.
Task automatability	claude-haiku-4-5-20251001	2/5	UI/UX improvement requires creative design decisions, user research synthesis, and domain expertise in bioinformatics workflows. While AI can generate layout suggestions or code snippets, end-to-end interface design with iterative testing and domain-specific usability optimization remains heavily dependent on human judgment and user feedback.
Task automatability	claude-sonnet-5	2/5	UI improvement for specialized scientific software requires domain-specific UX judgment, user research, and iterative testing that current AI cannot fully replace, though it can assist with code generation and mockups.'
Adoption barriers	claude-haiku-4-5-20251001	4/5	Bioinformatics software serves regulated research and clinical contexts where UI decisions impact data integrity and regulatory compliance. Organizational processes typically require human sign-off from domain experts and usability testing before deployment, creating adoption friction.
Adoption barriers	claude-sonnet-5	2/5	No licensing requirement, but organizational friction exists since interface changes require domain expert validation and integration with existing scientific workflows and databases.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	Current AI-assisted UI design tools reduce some design labor costs but require substantial expert review and iteration. The combination of inference, integration, and mandatory domain-expert validation makes the total cost comparable to or potentially higher than hiring a skilled UI/UX designer for bioinformatics.
Cost vs. human wage	claude-sonnet-5	2/5	Human UX/UI designers plus bioinformatics domain expertise remain necessary for meaningful improvements; AI tools reduce some coding time but oversight and domain validation costs keep overall savings modest.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	AI tools can assist with code generation and design mockups, but no mature product reliably performs holistic UI improvement for specialized bioinformatics software. Production systems lack the domain context and user interaction understanding needed to meaningfully enhance interfaces without expert oversight.
Technical feasibility today	claude-sonnet-5	2/5	AI coding assistants can generate UI components and suggest design patterns, but no deployed product autonomously redesigns bioinformatics-specific interfaces reliably without heavy human direction.

Consult with researchers to analyze problems, recommend technology-based solutions, or determine computational strategies.

CI 25–32 · exposure 25 · augmentation 75 · importance 4.2/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	While bioinformatics teams increasingly use AI tools for data analysis and code generation, adoption of AI-driven consultation on research strategy and technology recommendations remains limited to pilots and early adoption; most institutions still rely on human scientist consultation for strategic guidance.
Sector adoption velocity	claude-sonnet-5	3/5	Life sciences and bioinformatics are increasingly adopting AI tools (e.g., for literature review, coding assistance) but production-grade adoption for full computational strategy consultation remains limited and pilot-stage.
Augmentation potential	claude-haiku-4-5-20251001	4/5	AI can significantly augment bioinformatics scientists by rapidly generating candidate computational solutions, surveying literature and tool options, and drafting analysis strategies, allowing the human scientist to focus on evaluating fit, understanding trade-offs, and making context-aware strategic decisions during consultation with colleagues.
Augmentation potential	claude-sonnet-5	4/5	AI tools like coding assistants, literature summarizers, and analysis recommendation systems substantially speed up parts of this consultative and strategic work while the scientist retains final judgment.
Task automatability	claude-haiku-4-5-20251001	2/5	While AI can assist with problem analysis and suggest computational approaches, the core task requires understanding nuanced research contexts, collaborating with domain experts, and making strategic recommendations that depend on tacit knowledge of specific laboratory constraints and goals. Current AI cannot reliably replace the consultative dialogue and contextual judgment needed.
Task automatability	claude-sonnet-5	2/5	This task requires interactive consultation, contextual judgment about specific research goals, and creative problem framing that current AI cannot reliably replace end-to-end, though it can assist with pieces of the analysis.'
Adoption barriers	claude-haiku-4-5-20251001	4/5	Research institutions and funding bodies typically expect human expert consultation on research strategy; liability concerns over flawed computational recommendations, peer-review expectations for human expertise attribution, and organizational norms around research guidance create substantial friction against full automation of this consultative role.
Adoption barriers	claude-sonnet-5	3/5	No formal licensing requirement exists, but the task involves trust, scientific credibility, and accountability for recommending strategies that affect research outcomes, creating moderate organizational friction against full automation.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	AI inference for suggesting computational strategies is inexpensive, but effective consultation requires human bioinformatics expertise to validate, contextualize, and refine AI suggestions—meaning the full service still requires substantial expert labor cost, keeping total cost per task above or comparable to direct human consultation.
Cost vs. human wage	claude-sonnet-5	2/5	Given the need for extensive human oversight, validation, and domain-specific judgment, AI assistance reduces but does not eliminate the cost of a skilled bioinformatics scientist for this consultative task.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	LLMs and specialized bioinformatics tools can generate suggestions for computational strategies and identify relevant technologies, but production systems lack reliable ability to conduct true two-way consultative analysis with researchers or validate recommendations against specific project requirements and constraints in a deployed, trustworthy manner.
Technical feasibility today	claude-sonnet-5	2/5	AI chatbots and copilots can suggest algorithms or tools, but no deployed product reliably substitutes for expert consultation on computational strategy in bioinformatics research settings.

Recommend new systems and processes to improve operations.

CI 25–32 · exposure 25 · augmentation 63 · importance 3.0/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Adoption of AI for operational recommendations in bioinformatics remains limited. Most organizations still rely on internal process improvement teams and consultants; AI-driven recommendation systems in this context are not widely deployed in production settings.
Sector adoption velocity	claude-sonnet-5	3/5	Bioinformatics and biotech sectors are adopting AI tools for data analysis and literature synthesis at a moderate pace, but full-scale AI-driven operational recommendation systems remain in pilot stages.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI can assist by analyzing operational data, identifying bottlenecks, and surfacing candidate improvements that a human bioinformatics manager or consultant then evaluates and prioritizes. This assistive role improves the speed and breadth of analysis without removing human judgment from final recommendations.
Augmentation potential	claude-sonnet-5	4/5	AI can strongly assist by summarizing literature, benchmarking tools/pipelines, analyzing performance data, and drafting recommendation reports, significantly boosting the scientist's productivity while they retain final judgment.
Task automatability	claude-haiku-4-5-20251001	2/5	Recommending improvements requires domain expertise, strategic judgment, and understanding organizational context that current AI systems struggle with in a reliable, end-to-end manner. While AI can surface optimization suggestions based on data, the synthesis of operational constraints, feasibility assessment, and stakeholder priorities remains heavily human-dependent.
Task automatability	claude-sonnet-5	2/5	This requires synthesizing domain expertise, organizational context, and judgment about lab/IT workflows to generate viable recommendations; AI can assist with drafting and analysis but cannot autonomously produce validated, actionable operational recommendations end-to-end.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Operational decisions carry organizational risk and typically require sign-off from human managers and domain experts; there is strong preference for human accountability in recommending changes that affect research productivity and compliance. Liability for poor recommendations falls on the organization, creating a structural barrier to full automation.
Adoption barriers	claude-sonnet-5	3/5	No strict licensing requirement, but organizational risk tolerance, need for domain-specific validation, and internal approval processes create meaningful friction against fully automating this recommendation task.
Cost vs. human wage	claude-haiku-4-5-20251001	2/5	The cost of setting up AI-driven recommendation systems with sufficient accuracy, plus the human expertise needed to validate and implement suggestions, often exceeds the cost of direct expert consultation. Human bioinformatics scientists can provide recommendations more efficiently for specialized operational contexts.
Cost vs. human wage	claude-sonnet-5	2/5	Because human oversight, domain validation, and organizational buy-in are required, the effective cost of using AI plus necessary human review is not substantially cheaper than having a scientist do the analysis directly.
Technical feasibility today	claude-haiku-4-5-20251001	2/5	No deployed product reliably performs end-to-end operational improvement recommendations for bioinformatics workflows at scale. Some analytical tools can flag inefficiencies or suggest process changes, but these typically require substantial human interpretation and validation rather than functioning as standalone recommendation systems.
Technical feasibility today	claude-sonnet-5	2/5	No deployed product autonomously recommends new bioinformatics systems/processes reliably in production; AI is used only as a supporting research or drafting tool, not as an independent decision-maker for operational change.

Confer with departments, such as marketing, business development, or operations, to coordinate product development or improvement.

CI 5–21 · exposure 8 · augmentation 50 · importance 3.0/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	1/5	Bioinformatics and life-science organizations maintain high standards for human oversight in cross-functional product decisions due to regulatory and safety concerns; adoption of AI-led coordination is minimal.
Sector adoption velocity	claude-sonnet-5	2/5	While biotech/pharma are adopting AI tools for technical work, cross-functional strategic coordination meetings remain a human-centric process with minimal AI displacement observed.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI can assist by preparing briefing documents, summarizing departmental requirements, or drafting communication templates, improving human coordinators' efficiency—but humans remain essential for actual negotiation and commitment-making.
Augmentation potential	claude-sonnet-5	3/5	AI can help prepare briefing materials, summarize technical data for non-technical stakeholders, or draft agendas, providing moderate support to the human conducting these conferrals.
Task automatability	claude-haiku-4-5-20251001	2/5	Cross-departmental coordination requires understanding nuanced business context, stakeholder priorities, and negotiation—tasks where current AI systems struggle. While AI can draft agendas or summarize meeting notes, it cannot reliably lead strategic conversations or make binding commitments on behalf of departments.
Task automatability	claude-sonnet-5	1/5	This is a live, multi-stakeholder coordination and negotiation activity requiring relationship-building, real-time judgment, and organizational context that current AI cannot substitute for end-to-end.'
Adoption barriers	claude-haiku-4-5-20251001	4/5	Strong barriers exist: organizational protocols typically require human sign-off on product decisions, stakeholder trust and accountability rest on human judgment, and liability for product choices falls on human decision-makers who must remain responsible.
Adoption barriers	claude-sonnet-5	3/5	No licensing requirement exists, but organizational trust, accountability for decisions, and the need for human relationship management create meaningful friction against automation.
Cost vs. human wage	claude-haiku-4-5-20251001	1/5	The overhead of AI oversight, validation, and human confirmation for coordination decisions far exceeds the cost of direct human conversation, especially since the task is inherently about human relationship-building and judgment.
Cost vs. human wage	claude-sonnet-5	1/5	Since AI cannot perform the core interpersonal coordination task, there is no viable AI substitute cost to compare against human labor for this function.
Technical feasibility today	claude-haiku-4-5-20251001	1/5	No deployed product reliably performs real cross-functional strategic coordination today. AI chatbots can simulate discussions but cannot conduct authentic multi-party stakeholder alignment or commit organizations to product decisions.
Technical feasibility today	claude-sonnet-5	1/5	No deployed product autonomously conducts cross-departmental strategic conferrals; at best AI tools support meeting prep or note-taking, not the actual conferring.

Direct the work of technicians and information technology staff applying bioinformatics tools or applications in areas such as proteomics, transcriptomics, metabolomics, or clinical bioinformatics.

CI 7–16 · exposure 8 · augmentation 50 · importance 3.5/5 · click for rater detail

Panel ratings per dimension for this task
Dimension	Model	Rating	Rationale
Sector adoption velocity	claude-haiku-4-5-20251001	2/5	Bioinformatics and research organizations digitize data workflows readily but remain conservative about automating managerial direction. Current adoption of AI for staff oversight is minimal; most sectors treat personnel management as a human function.
Sector adoption velocity	claude-sonnet-5	2/5	While bioinformatics as a field adopts computational tools quickly, the specific managerial/directing function sees little AI adoption in practice.
Augmentation potential	claude-haiku-4-5-20251001	3/5	AI can assist with task tracking, scheduling suggestions, documentation, and analysis of team performance metrics, thereby raising the director's effectiveness in parts of the role. However, augmentation is limited to administrative support; core judgment and people leadership remain human-centric.
Augmentation potential	claude-sonnet-5	3/5	AI tools can help the director analyze data, generate reports, or track project status, improving oversight efficiency, but the core directing function remains human-led.
Task automatability	claude-haiku-4-5-20251001	2/5	Directing staff work requires real-time judgment about priorities, personnel performance, and adaptive problem-solving in a research context. While AI could assist with scheduling or documentation, the core supervisory and decision-making aspects—evaluating technical decisions, mentoring, conflict resolution—remain fundamentally human and would save less than 50% time.
Task automatability	claude-sonnet-5	1/5	Directing and managing staff involves interpersonal leadership, prioritization, and judgment calls that AI cannot perform end-to-end; AI can assist with technical sub-tasks but not the managerial direction itself.
Adoption barriers	claude-haiku-4-5-20251001	4/5	Management and direction of personnel carry inherent legal, liability, and organizational barriers. Employment law, performance evaluation, and organizational hierarchy require a human supervisor with accountability and decision authority; substitution faces hard friction.
Adoption barriers	claude-sonnet-5	4/5	Managerial authority, accountability for staff decisions, and organizational hierarchy create strong structural barriers to AI replacing a human director in this role.
Cost vs. human wage	claude-haiku-4-5-20251001	1/5	AI cannot substitute for the salary and expertise of a bioinformatics director who oversees technicians and IT staff. The all-in cost of attempting to automate through AI tools (inference, integration, oversight by a human manager) would exceed the cost of retaining the human director.
Cost vs. human wage	claude-sonnet-5	1/5	There is no AI substitute performing this managerial task, so cost comparison favors the human entirely.
Technical feasibility today	claude-haiku-4-5-20251001	1/5	No deployed product reliably performs management and direction of technical teams in bioinformatics settings. AI systems cannot assess subordinate competence, make personnel decisions, or provide the adaptive guidance required in a live research environment.
Technical feasibility today	claude-sonnet-5	1/5	No deployed product manages or directs human technicians and IT staff in an organizational sense; this remains a human management function.

Related occupations — Life, Physical & Social Science

How to read this

A high substitution score does not mean this job disappears — it means a large share of its current tasks face replacement pressure, so the mix of tasks is likely to change. High augmentation alongside substitution typically means the occupation reorganizes around the protected tasks. Wide confidence intervals mean the rater panel disagreed: treat those scores as open questions, not verdicts.

What would change this score

New model capabilities (automatability, feasibility), falling inference costs (cost ratio), regulation and licensing shifts (barriers), and measured sector adoption (velocity) all re-enter at every index release. Each release is recomputed, versioned and kept queryable — scores are claims with a date on them, not permanent labels.